Skip to main content

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Philip Johnson

Philip Johnson is recorded as CFO at Jazz Pharmaceuticals plc (JAZZ). Jazz Pharmaceuticals plc reported in an 8-K filed February 21, 2024 that Philip Johnson was appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024. The proxy statement of Jazz Pharmaceuticals plc reports total compensation of $7,544,473 for Philip Johnson in fiscal 2025, including a base salary of $741,346. Disclosed compensation is on record for 2 fiscal years. Philip Johnson has spoken on 10 earnings calls across 1 company, most recently for Jazz Pharmaceuticals plc on August 3, 2026.

“On February 21, 2024, Jazz Pharmaceuticals plc (the "Company") announced the appointment of Philip Johnson as the Company's Executive Vice President and Chief Financial Officer, effective as of March 1, 2024.”
Jazz Pharmaceuticals plc Form 8-K, filed February 21, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Jazz Pharmaceuticals plc

Other people whose current roles at this company are on record from its filings.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Jazz Pharmaceuticals plc (JAZZ) $741,346 $7,544,473
2024 Jazz Pharmaceuticals plc (JAZZ) $581,539 $5,243,445

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.